The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
O'Connor brings over 30 years of leadership experience in the biotechnology and oncology sectors
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
